A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma

International Journal of Oncology

Volumn 44, Issue 4, 2014, Pages 1146-1152

  Yusup, Gulbostan ^a   Akutsu, Yasunori ^a   Mutallip, Muradil ^a   Qin, Wei ^a   Hu, Xin ^a   Komatsu Akimoto, Aki ^a   Hoshino, Isamu ^a   Hanari, Naoyuki ^a   Mori, Mikito ^a   Akanuma, Naoki ^a   Isozaki, Yuka ^a   Matsubara, Hisahiro ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 inhibitor; Esophageal cancer; Squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; MESSENGER RNA; OROTATE PHOSPHORIBOSYLTRANSFERASE; PROSTAGLANDIN; PTGS2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; RADIOSENSITIZING AGENT; SULFONAMIDE;

APOPTOSIS; BIOSYNTHESIS; CARCINOMA, SQUAMOUS CELL; CELL MOTION; DRUG EFFECTS; ESOPHAGEAL NEOPLASMS; GENETICS; HUMAN; METABOLISM; TUMOR CELL LINE; TUMOR INVASION;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DIHYDROURACIL DEHYDROGENASE (NADP); ESOPHAGEAL NEOPLASMS; FLUOROURACIL; HUMANS; NEOPLASM INVASIVENESS; OROTATE PHOSPHORIBOSYLTRANSFERASE; PROSTAGLANDINS; PYRAZOLES; RADIATION-SENSITIZING AGENTS; RNA, MESSENGER; SULFONAMIDES;

EID: 84894421960     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2300     Document Type: Article

References (39)

1. Pennathur A, Gibson MK, Jobe BA and Luketich JD: Oesophageal carcinoma. Lancet 381: 400-412, 2013.
2. Siersema PD: Esophageal cancer. Gastroenterol Clin North Am 37: 943-964, 2008.
3. Rizzo MT: Cyclooxygenase-2 in oncogenesis. Clin Chim Acta 412: 671-687, 2011.
4. Smith WL, DeWitt DL and Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182, 2000.
5. Dempke W, Rie C, Grothey A and Schmoll HJ: Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 127: 411-417, 2001.
6. Shamma A, Yamamoto H, Doki Y, et al: Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin Cancer Res 6: 1229-1238, 2000.
7. Hida T, Yatabe Y, Achiwa H, et al: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58: 3761-3764, 1998.
8. Dannenberg AJ and Subbaramaiah K: Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4: 431-436, 2003.
9. Okamura H, Fujiwara H, Umehara S, et al: COX-2 overexpression Induced by gene transfer reduces sensitivity of TE13 esophageal carcinoma cells to 5-fluorouracil and cisplatin. Anticancer Res 33: 537-542, 2013.
10. Higashi Y, Kanekura T and Kanzaki T: Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression. Int J Cancer 86: 667-671, 2000.
11. Lucci A, Krishnamurthy S, Singh B, et al: Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Res Treat 117: 61-68, 2009.
12. Van Nes JG, de Kruijf EM, Faratian D, et al: COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Res Treat 125: 671-685, 2011.
13. Hashimoto N, Inayama M, Fujishima M and Shiozaki H: Clinicopathologic significance of expression of cyclooxygenase-2 in human esophageal squamous cell carcinoma. Hepatogastroenterology 54: 758-760, 2007.
14. Akutsu Y, Hanari N, Yusup G, et al: COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma. Ann Surg Oncol 18: 2946-2951, 2011.
15. Jendrossek V: Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett 332: 313-324, 2013.
16. Boolbol SK, Dannenberg AJ, Chadburn A, et al: Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56: 2556-2560, 1996.
17. Tsujii M, Kawano S and DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94: 3336-3340, 1997.
18. Kwak YE, Jeon NK, Kim J and Lee EJ: The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma. Ann NY Acad Sci 1095: 99-112, 2007.
19. Dai ZJ, Ma XB, Kang HF, et al: Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in vitro and in vivo. Cancer Cell Int 12: 53, 2012.
20. Soslow RA, Dannenberg AJ, Rush D, et al: COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89: 2637-2645, 2000.
21. Gupta S, Srivastava M, Ahmad N, Bostwick DG and Mukhtar H: Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42: 73-78, 2000.
22. Sano H, Kawahito Y, Wilder RL, et al: Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55: 3785-3789, 1995.
23. Hwang D, Scollard D, Byrne J and Levine E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90: 455-460, 1998.
24. De Groot DJ, de Vries EG, Groen HJ and de Jong S: Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit Rev Oncol Hematol 61: 52-69, 2007.
25. Takemura M, Morimura K, Yoshida K and Fujiwara Y: Four resected cases with basaloid carcinoma of esophagus - comparison of 5-FU-related enzymes (thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT)) between basaloid carcinoma and squamous cell carcinoma. Gan To Kagaku Ryoho 37: 2143-2146, 2010 (In Japanese).
26. Ofverholm A, Arkblad E, Skrtic S, Albertsson P, Shubbar E and Enerback C: Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene. Clin Biochem 43: 331-334, 2010.
27. Ostapowicz A and Dolegowska B: Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil. Przegl Lek 69: 694-697, 2012 (In Polish).
28. Li WZ, Huo QJ, Wang XY and Xu F: Inhibitive effect of celecoxib on the adhesion and invasion of human tongue squamous carcinoma cells to extracellular matrix via down regulation of MMP-2 expression. Prostaglandins Other Lipid Mediat 93: 113-119, 2010.
29. Sheng H, Shao J, Morrow JD, Beauchamp RD and DuBois RN: Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58: 362-366, 1998.
30. Oshima H and Oshima M: The role of PGE2-associated inflammatory responses in gastric cancer development. Semin Immunopathol 35: 139-150, 2013.
31. Cianchi F, Cortesini C, Bechi P, et al: Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 121: 1339-1347, 2001.
32. Elder DJ, Halton DE, Crew TE and Paraskeva C: Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398. Int J Cancer 86: 553-560, 2000.
33. Irie T, Tsujii M, Tsuji S, et al: Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-gamma. Int J Cancer 121: 878-883, 2007.
34. Kuipers GK, Slotman BJ, Wedekind LE, et al: Radiosensitization of human glioma cells by cyclooxygenase-2 (COX-2) inhibition: independent on COX-2 expression and dependent on the COX-2 inhibitor and sequence of administration. Int J Radiat Biol 83: 677-685, 2007.
35. Shin YK, Park JS, Kim HS, et al: Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res 65: 9501-9509, 2005.
36. Jun HJ, Kim YM, Park SY, et al: Modulation of ionizing radiation-induced G2 arrest by cyclooxygenase-2 and its inhibitor celecoxib. Int J Radiat Oncol Biol Phys 75: 225-234, 2009.
37. Davis TW, O'Neal JM, Pagel MD, et al: Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Res 64: 279-285, 2004.
38. Kim BM, Won J, Maeng KA, Han YS, Yun YS and Hong SH: Nimesulide, a selective COX-2 inhibitor, acts synergistically with ionizing radiation against A549 human lung cancer cells through the activation of caspase-8 and caspase-3. Int J Oncol 34: 1467-1473, 2009.
39. Raju U, Ariga H, Dittmann K, Nakata E, Ang KK and Milas L: Inhibition of DNA repair as a mechanism of enhanced radio-response of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib. Int J Radiat Oncol Biol Phys 63: 520-528, 2005.